Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 344 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Skin Biopsy Clear all
Completed No phase listed Observational

Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil

NCT00853788
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
19 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

NCT04032080
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Drug 1: LY3023414; Drug 2: Prexasertib
Combination Product
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 9, 2026, 3:16 AM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 9, 2026, 3:16 AM EDT
Recruiting No phase listed Observational

Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency

NCT03758521
View directory record Official record
Conditions
Succinic Semialdehyde Dehydrogenase Deficiency
Interventions
Transcranial magnetic stimulation (TMS), Magnetic resonance imaging (MRI), Electroencephalogram (EEG), Bio-specimen Collection
Device · Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Not listed Not applicable Interventional

Non-Ambulatory SCI Walk Using a Robotic Exoskeleton: Effect on Bone and Muscle

NCT02324322
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Exoskeleton Training, Muscle Biopsies, MRI
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
21 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies

NCT03918356
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies
Interventions
electrical impedance myography, healthy control group
Device · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 9, 2026, 3:16 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells

NCT00482105
View directory record Official record
Conditions
Melanoma
Interventions
EGIR Tape
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional

Landmark vs. Ultrasound-Assisted Bone Marrow Biopsy Procedure Study

NCT05258357
View directory record Official record
Conditions
Bone Marrow Biopsy Procedure
Interventions
Ultrasound-assisted bone marrow biopsy, Landmark palpation bone marrow biopsy
Device · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

NCT03270241
View directory record Official record
Conditions
Vitiligo, Dermatology/Skin - Other
Interventions
Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 9, 2026, 3:16 AM EDT
Recruiting Phase 4 Interventional

Ethnic Differences in Mechanisms of Action of Dupilumab

NCT05268107
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional

Effect of Radiation on Tissue for Delayed Breast Reconstruction

NCT01666899
View directory record Official record
Conditions
Breast Cancer
Interventions
Skin and blood vessel procedures
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 9, 2026, 3:16 AM EDT
Completed No phase listed Observational

Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques

NCT02393001
View directory record Official record
Conditions
Melanoma
Interventions
Dermatology patients
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 9, 2026, 3:16 AM EDT
Not listed Phase 4 Interventional

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

NCT05265234
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 9, 2026, 3:16 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
CDX-301, NEOVAX, Nivolumab, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 9, 2026, 3:16 AM EDT
Completed No phase listed Observational

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

NCT01276899
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsies, Needle core biopsies of metastatic lesion
Procedure
Lead sponsor
Jewish General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 2 Interventional

A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)

NCT00015626
View directory record Official record
Conditions
Insulin Resistance, Diabetes Mellitus
Interventions
Metformin, skin biopsy, diet and exercise, pioglitazone, rosiglitazone
Drug · Procedure · Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 3:16 AM EDT
Active, not recruiting Phase 2 Interventional

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

NCT02756962
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Allogeneic stem cell transplant, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Drug · Procedure · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo

NCT00367224
View directory record Official record
Conditions
Vitiligo
Interventions
6 to 9 ultraviolet B treatments, Skin biopsies
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 9, 2026, 3:16 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dose Regimen Study of SLI-F06 in Healthy Volunteers

NCT05501327
View directory record Official record
Conditions
Scar, Wound Healing
Interventions
SLI-F06
Drug
Lead sponsor
Scarless Laboratories, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Encinitas, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 9, 2026, 3:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
Interventions
Tagraxofusp, Azacitidine (AZA), Venetoclax
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Recruiting Phase 2 Interventional

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

NCT06510361
View directory record Official record
Conditions
Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Interventions
Epcoritamab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

Xenodiagnosis After Antibiotic Treatment for Lyme Disease

NCT02446626
View directory record Official record
Conditions
Lyme Disease
Interventions
Skin biopsy, Blood draw, Xenodiagnosis
Procedure · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Storrs, Connecticut • Bethesda, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 9, 2026, 3:16 AM EDT
Terminated Phase 1 Interventional

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

NCT03982004
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Epicutaneous cryoimmunotherapy, Topical imiquimod, Pembrolizumab, Dermatologic Quality of Life Index, Functional Assessment of Cancer Therapy, Intra-lesional GM-CSF, Cry-AC, Cutaneous tumor biopsy, Peripheral blood draw for research
Device · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 9, 2026, 3:16 AM EDT